As Co-Chairs of the 2017 ISPE Process Validation Statistics Conference, we are pleased to invite you to join us in Bethesda, Maryland, 13 – 15 September as we explore evolving and state-of-the-art approaches to implementing statistics in process validation.
This exceptional forum has become a converging point for statisticians and those skilled in the use of statistics to reflect on past practices, discuss current trends, and consider future challenges. You’ll have the opportunity to interact with regulatory experts and leading practitioners as they share their current thoughts on the relationship of statistics, validation decisions, and patient risk.
You will also actively participate in discussion groups exploring current challenges chosen by attendees, and an open forum session on the recent EMA reflection paper on comparability assessment of quality attributes. Dr. Kit Roes, University Medical Center Utrecht, will provide additional insight into this effort in his keynote address.
This year’s conference will expand your knowledge on:
You can also sharpen your process validation knowledge by taking advantage of the 2017 ISPE Process Validation Conference, which takes place right before the Process Validation Statistics Conference. Save an additional 25% by registering for both conferences.
For more information and to register for the 2017 ISPE Process Validation Conference, please visit the conference website.
We look forward to seeing you in September!
Best Regards,
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...